Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Passage Bio ( (PASG) ) has provided an update.
On March 3, 2026, Passage Bio reported its fourth quarter and full-year 2025 results and detailed progress in its PBFT02 program for frontotemporal dementia. During 2025, the company enrolled the first three FTD-GRN patients into Cohort 3 of its global Phase 1/2 upliFT-D trial and, under an amended protocol targeting earlier-stage patients, moved toward dosing a total of 10 participants across five countries.
The company also treated the first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4, with safety oversight by an independent data monitoring committee before enrolling additional patients. Passage Bio highlighted a differentiated preclinical Huntington’s disease program using an AAV-delivered miRNA against MSH3, and it maintained a $46.3 million cash position at year-end 2025, guiding a runway through the first quarter of 2027 as R&D and net losses declined versus 2024.
Management indicated it was on track in the first half of 2026 to deliver updated interim safety and biomarker data from upliFT-D and to seek regulatory feedback on a registrational trial design for FTD-GRN. These operational milestones and extended cash runway support Passage Bio’s positioning as a focused CNS gene therapy player, with near-term clinical readouts and regulatory interactions likely to be key for investors and other stakeholders monitoring its path toward late-stage development.
The most recent analyst rating on (PASG) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Passage Bio stock, see the PASG Stock Forecast page.
Spark’s Take on PASG Stock
According to Spark, TipRanks’ AI Analyst, PASG is a Neutral.
The score is held back primarily by weak financial fundamentals typical of a pre-revenue biotech (ongoing losses and negative free cash flow, with signs of increasing financing reliance). Technicals are a supportive offset with strong momentum above major moving averages, but overbought readings temper the benefit. Valuation is limited by the negative P/E and the absence of a dividend yield.
To see Spark’s full report on PASG stock, click here.
More about Passage Bio
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing one-time therapies for neurodegenerative diseases. Its lead candidate, PBFT02, targets genetic forms of frontotemporal dementia by elevating progranulin levels to restore lysosomal function and slow disease progression, with additional preclinical work underway in Huntington’s disease.
Average Trading Volume: 60,349
Technical Sentiment Signal: Strong Sell
Current Market Cap: $27.4M
See more insights into PASG stock on TipRanks’ Stock Analysis page.